We could program cells to produce a given amount of a particular protein over a specified time period?
We can design cellular software – in the form of messenger RNA – that allows people to make their own vaccines and medicines in a controllable and reversible way.
Founded in 2010 by Flagship Pioneering, Moderna (NASDAQ: MRNA) is focused on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, a new class of potential medicines that directs the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.
Moderna is creating potential mRNA medicines for a wide range of diseases and conditions which currently include infectious diseases, oncology, rare genetic diseases, and cardiovascular diseases. Moderna is developing these potential medicines independently and through strategic alliances with collaborators, including AstraZeneca, Merck, and Vertex Pharmaceuticals, as well as the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), and the Bill & Melinda Gates Foundation.
Latest Press from Moderna
- Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic 02.20.2019
- Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 02.12.2019
- Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial 02.05.2019
- Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors 01.30.2019
- Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner 01.18.2019
- Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives 01.08.2019